Thomas Lavery | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Goodwin Procter LLP

Biosimilar or Biodifferent: How a Name Will Shape the Market for Biosimilars
Wednesday, November 19, 2014
Whether biosimilars and interchangeable biologics should share the same nonproprietary name as their reference products has been hotly debated.

2026 Company Focus & Industry Reference Guide
View Issue

Subscriptions

Get started here for yourcomplimentary print ordigital subscription

Get started here for your complimentary magazine subscription

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.